Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

• Main Authors: Li X (Author), Lin X (Author), Wu Z (Author), Su Y (Author), Liang J (Author), Chen R (Author), Yang X (Author), Hou L (Author), Zhao J (Author), Liu Q (Author), Xu F (Author)
• Format: Book
• Published: Dove Medical Press, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Xuedong Li,1,2,* Xixi Lin,1,2,* Zuoxing Wu,3 Yuangang Su,1,2 Jiamin Liang,1,2 Runfeng Chen,1,2 Xue Yang,1,2 Lei Hou,4 Jinmin Zhao,1,5 Qian Liu,5 Feng Xu1,2,6 1Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi 530021, People’s Republic of China; 2Guangxi Co...